Bristol-Myers Squibb Company (BMY)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 37.48% | 36.88% | 37.15% | 38.42% | 38.38% | 36.57% | 37.38% | 37.07% | 34.92% | 46.15% | 54.63% | 63.19% | 72.31% | 71.18% | 69.47% | 68.02% | 69.10% | 69.98% | 70.26% | 71.11% |
| Operating profit margin | -21.12% | -23.00% | -23.45% | -21.49% | -22.27% | -26.38% | -26.60% | -29.85% | -33.39% | -3.96% | -5.43% | -7.11% | -7.80% | -15.29% | 2.89% | 15.45% | 33.57% | 31.47% | 19.46% | 17.50% |
| Pretax margin | 18.72% | 19.15% | 19.22% | 19.15% | 16.67% | 16.47% | 16.21% | 15.41% | 17.42% | -9.31% | -9.31% | -9.47% | -16.21% | 8.72% | 7.23% | 8.60% | 18.95% | 27.25% | 31.04% | 26.39% |
| Net profit margin | 17.83% | 18.44% | 17.62% | 15.95% | 13.71% | 14.29% | 14.04% | 13.31% | 15.08% | -11.89% | -11.44% | -14.53% | -21.20% | -0.11% | -1.61% | 3.08% | 13.15% | 23.39% | 26.00% | 22.09% |
Bristol-Myers Squibb Co. has maintained relatively stable gross profit margins over the past eight quarters, averaging around 77%. This indicates the company's ability to efficiently manage its cost of goods sold and generate profits from its products.
In terms of operating profit margin, Bristol-Myers Squibb Co. has shown some fluctuations, with the highest margin recorded in Q4 2022 at 20.67% and the lowest in Q1 2023 at 17.64%. The company's operating profit margin has averaged around 18.6% over the last eight quarters, indicating its operational efficiency in generating profits from its core business activities.
The pretax margin has also shown variability, ranging from 15.45% in Q1 2022 to 19.25% in Q2 2023. The average pretax margin for Bristol-Myers Squibb Co. over the eight quarters is approximately 17.9%, reflecting the company's ability to manage its expenses and taxes effectively.
Lastly, the net profit margin for Bristol-Myers Squibb Co. has been consistent overall, averaging around 16.4% over the past two years. This indicates the company's ability to generate profits after accounting for all expenses, including taxes and interest. Overall, Bristol-Myers Squibb Co. has shown solid profitability ratios, reflecting its ability to efficiently convert revenue into profits.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -9.99% | -11.33% | -11.34% | -10.45% | -10.62% | -12.56% | -12.49% | -13.60% | -14.17% | -1.62% | -2.18% | -2.71% | -2.80% | -4.80% | 0.79% | 3.70% | 6.76% | 13.25% | 8.42% | 11.70% |
| Return on assets (ROA) | 8.43% | 9.08% | 8.52% | 7.75% | 6.53% | 6.80% | 6.59% | 6.07% | 6.40% | -4.87% | -4.58% | -5.53% | -7.61% | -0.04% | -0.44% | 0.74% | 2.65% | 9.85% | 11.24% | 14.77% |
| Return on total capital | 14.51% | 15.95% | 14.78% | 14.91% | 13.50% | 12.86% | 12.81% | 12.38% | 12.46% | -3.73% | -3.46% | -3.22% | -6.35% | 5.22% | 4.10% | 3.92% | 5.91% | 16.68% | 18.94% | 30.34% |
| Return on equity (ROE) | 27.27% | 28.57% | 24.91% | 22.97% | 20.37% | 20.44% | 20.30% | 19.79% | 19.46% | -14.52% | -13.80% | -16.54% | -23.84% | -0.09% | -1.15% | 1.91% | 6.66% | 32.04% | 38.65% | 33.80% |
Bristol-Myers Squibb Co.'s profitability ratios present a mixed performance over the past eight quarters.
1. Operating return on assets (Operating ROA) has been relatively stable, ranging from 8.61% to 9.40% over the period. This indicates that the company is effectively generating operating profits from its assets.
2. Return on assets (ROA) has shown some variability, with a low of 6.07% in Q1 2022 and a high of 9.08% in Q3 2023. This metric reflects the company's overall ability to generate profits from all its assets.
3. Return on total capital has been on an upward trend since Q1 2022, reaching a high of 13.43% in Q1 2023. This metric demonstrates how efficiently the company is utilizing all its capital to generate returns.
4. Return on equity (ROE) has also shown an increasing trend, indicating that Bristol-Myers Squibb Co. is generating higher returns for its equity shareholders. The ROE ranged from 19.79% to 28.57% over the past eight quarters.
Overall, Bristol-Myers Squibb Co. has demonstrated solid profitability metrics, with improvements in ROE and return on total capital. However, some volatility in ROA indicates the need for further analysis to understand the underlying factors driving these fluctuations.
See also:
Bristol-Myers Squibb Company Profitability Ratios (Quarterly Data)